Overview

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Status:
Completed
Trial end date:
2018-03-14
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel group study to compare systemic exposure of triamcinolone acetonide following administration into both knees of either FX006 or TAcs.
Phase:
Phase 2
Details
Lead Sponsor:
Flexion Therapeutics, Inc.
Treatments:
FX006
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide